retatrutide obesity clinical trial results in 28 percent average weight loss Incretin triple agonist retatrutide (LY3437943)

If you're expecting the medication alone to solve weight management challenges without behavior change, you are likely to be disappointed

What is your favorite product from this brand

Injection site reactions represent another category of commonly observed side effects

This decline happens across multiple species, including rodents and humans

The request comes after a safety review that analyzed nearly 100 placebo-controlled clinical trials with over 106,000 patients and found no increased risk of suicidal thoughts or behavior related to GLP-1 use

Never increase, decrease, or repeat a dose simply because another patient received different syringe-unit instructions